{"id":"xr-tacrolimus-qd-mmf-bid","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Gastrointestinal disturbances (diarrhea, nausea)"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL3989887","moleculeType":"Small molecule","molecularWeight":"822.05"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus is a calcineurin inhibitor that blocks T-cell receptor signaling by inhibiting calcineurin phosphatase, preventing IL-2 production and T-cell activation. Mycophenolate mofetil (MMF) is a selective inhibitor of inosine monophosphate dehydrogenase (IMPDH) that depletes guanosine nucleotides in T and B lymphocytes, further suppressing immune proliferation. Together, they provide synergistic immunosuppression for transplant rejection prevention.","oneSentence":"XR-tacrolimus and MMF work together as immunosuppressants to prevent organ rejection by inhibiting T-cell activation and proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:25.248Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (renal, cardiac, hepatic transplantation)"}]},"trialDetails":[{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"XR-tacrolimus QD + MMF BID","genericName":"XR-tacrolimus QD + MMF BID","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"XR-tacrolimus and MMF work together as immunosuppressants to prevent organ rejection by inhibiting T-cell activation and proliferation. Used for Prevention of organ rejection in transplant recipients (renal, cardiac, hepatic transplantation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}